Sana Biotechnology, Inc. (SANA)
|Net Income (ttm)||-215.18M|
The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company's cell-based therapy dis...
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...
Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering.
Sana Biotechnology, Inc. has filed to go public with an IPO on the NASDAQ.
UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue ...
Sana Biotechnology was founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access t... [Read more...]
|IPO Date |
Steven D. Harr, M.D.
|Stock Exchange |
|Ticker Symbol |